Collegium Pharmaceutical

Published
Oct 23, 2025 11:49AM EDT
Live From MarketSite 2025
About This Series With Kristina Ayanian

Nasdaq Listings Host Kristina Ayanian delves into companies' notable accomplishments, industry trends, and the driving factors behind their success through engaging conversations with C-suite executives and industry leaders.

Vikram Karnani, CEO of Collegium Pharmaceutical (NSDQ: COLL), sits down with Nasdaq’s Kristina Ayanian to discuss the company’s 10-year anniversary as a publicly traded firm. He shares insights on Collegium’s growth, impact on the ADHD community, and what investors can expect as the company looks ahead to 2026 and beyond.

Transcripts

No transcript available